Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Prevalence of Fibromyalgia in France

Thursday 17 November 2011

From BMC Musculoskeletal Disorders:


French flagPrevalence of Fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: The DEFI study (Determination of Epidemiology of Fibromyalgia).

Serge Perrot1 email, Eric Vicaut2 email, Dominique Servant3 email and Philippe Ravaud4 email

Service de Médecine Interne et Thérapeutique, Hôtel Dieu, Université Paris Descartes, INSERM U 987, 1 Place du Parvis Notre Dame, 75004 Paris, France

Unité de Recherche Clinique, Hôpital Lariboisière, 2 Rue Ambroise Paré, 75010 Paris, France

Unité Stress et Anxiété, Hôpital Fontan, CHRU de Lille, 6 Rue André Verhaeghe 59037 Lille Cedex, France

Département d'épidémiologie, Hôtel Dieu, Université Paris Descartes, 1 Place du Parvis Notre Dame, 75004 Paris, France

email author email     email corresponding author email

BMC Musculoskeletal Disorders 2011, 12:224 doi:10.1186/1471-2474-12-224

Published: 7 October 2011


Fibromyalgia is a common disease, but little is known on its real prevalence in France. This epidemiological study aimed to assess fibromyalgia (FM) prevalence in the French metropolitan population, based on a multi-step sampling analysis, combining national screening and clinical confirmation by trained specialists.

A sampling method on the entire national territory was used: patients over 18 years of age accepting to take part in the study were contacted by telephone using the LFES Questionnaire, a screening test for FM. The, for patients detected by the LFESQ, a visit with a FM-trained rheumatologist was proposed to confirm FM, based on 1990 ACR criteria. Each detected patient completed the following self-questionnaires: SF36, HADS, stress VAS, Co-morbidities and Regional pain score.

3081 patients were contacted in 5 representative French regions, of which 232 patients were screened for FM. A fibromyalgia diagnosis was then confirmed by rheumatologist in 20 cases (17 female and 3 male, 56.9 ± 13.2 years). The final estimated FM prevalence was 1.6 (CI95: 1.2%; 2.0%). No significant difference was detected between the patients accepting (CS+) and refusing (CS-) rheumatologist visit for the SF36 score, regional pain score, stress VAS scale and co-morbidities. In patients detected for FM by the LFESQ, we found a statistically significant decrease in quality of life and a statistically significant increase in stress level in patients with a confirmed diagnosis (FM+) (6.3 ± 1.9) compared to patients with an invalidated diagnosis (FM-) (4.4 ± 2.8; p = 0.007). The study also demonstrated a significant association, independently of ACR criteria, between the diagnosis of FM and several factors such as regional pain score > 10, elevated stress level, low SF36 scale score and presence of gastro-intestinal disorder co-morbidities.

Fibromyalgia is a common condition; the 1.6% prevalence calculated in the French population in our study corroborates the figures published in the European literature. Our results also suggest that criteria such as regional pain score, stress level or SF36 quality of life, could represent useful tools in fibromyalgia diagnosis.



The complete version of this article can be found online at:

Received: 16 June 2011
Accepted: 7 October 2011
Published: 7 October 2011

© 2011 Perrot et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The above originally appeared here.


Arrow right

More Fibromyalgia News



blog comments powered by Disqus
Previous Previous Page